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Notice	of	Requirements	for	Successful	Completion:		For	successful	completion,	
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program	evaluation	at	the	conclusion	of	the	educational	event.	
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AADE,	ANCC,	ACPE	or	CDR	of	any	commercial	products	displayed	in	conjunction	
with	this	educational	activity.	
Off-label	Use:		Participants	will	be	notified	by	speakers	to	any	product	used	for	a	
purpose	other	than	that	for	which	it	was	approved	by	the	Food	and	Drug	
Administration.	
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Outline		
• Diabetic	kidney	disease	epidemiology		
• Role	of	the	kidney	in	glucose	homeostasis		
• Sodium	glucose	contransporters	(SGLT)		
• Review	of	the	kidney	outcomes	in	
Cardiovascular	Outcomes	Trials	(CVOT)	
• Overview	of	CREDENCE		
• Field	guide	for	use	of	SGLT-2	inhibitors	circa	
mid-2019		
• Future	of	SLGTs	inhibitors		
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	Diabetic	Kidney	Disease		
(	DKD)		
• A	persistent	elevated	urinary	albumin	excretion	
(UAE)	≥30	mg/g,	a	persistent	reduction	in	
estimated	glomerular	filtration	rate	(eGFR)	<60	
ml/min/1.73	m2,	or	both		
• Epidemiological	data	show	that	about	30%	of	
patients	with	DM	1,	and	about		40%	of	DM	2	
patients	have	DKD		
• Post-mortem	human	studies	show	that	up	to	
60%	of	diabetic	patients	have	structural	changes	
of	DKD	
		Kidney	Disease	Improving	Global	Outcomes	www.kdigo.org	
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Natural	History	of	DKD	
Alicic	RZ	et	al.	Clin	J	Am	Soc	Nephrol	,	2017;	12:	2032–2045.	et	al.	CJASN	
2017;	12:2032-2045		
Diabetic	Kidney	Disease	
(	DKD)	
	
• World	wide	leading	cause	of	
ESKD	(in	US	about	44%	of	all	
dialysis	patients	have	
diabetes)		
• ESKD	and	need	for	KRT	=	
death	sentence	in	large	part	
of	the	world		
• The	global	number	of	deaths	
attributed	to	DKD	rose	by	
94%	between	1990-2012	
Courser	WG	et	al.	Kidney	Int	2011;80:1258	
Lozano	R	et	al.	Lancet	2012;	380:2095	
Mortality and Morbidity of DKD Patients  
• The	prevalence	of	cardiovascular	(CV)	
disease:	70%	among	patients	aged	66	and	
older	who	have	CKD	compared	with	35%	
among	those	who	don’t	have	CKD	
• Diabetic	patients	with	ESKD	have		10	to	100-
fold	higher	mortality	risk	
• Most	of	the	excess	all-cause	and	CV	death	
risk	in	diabetes	is	attributable	to	the	
presence	of	diabetic	kidney	disease	
	United	States	Renal	Data	System;	www.usrds.org	Adler	et	al.	Kidney	Int.	2003,63:225–232	
Afkarian	et	al.	J	Am	Soc	Nephrol.	2003,24:302-308.		
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Mortality	Rates	
Adler	et	al,	Kidney	Int,	2003;63(1):225–232	
Prevalence	of	Diabetic	Kidney	Disease	is	
Increasing	Despite	Contemporary	Management	
All	Diabetic	Kidney	Disease	
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De	Boer	et	al.	JAMA.	305:2532-2539,	2011	
Kidneys	and	Glucose	Homeostasis		
	
Physiologic	conditions	
-	Gluconeogenesis	(	20%-25%	)		
-	Reabsorption	of	glucose	in	the	kidney	(160-180	g/d	)		
- Uptake	of	glucose	from	the	circulation	(	10%)		
In	diabetes	
-  				Postabsorptive	gluconeogenesis		
-  				Reabsorption	of	glucose		in	the	kidney		
12	
Neumiller	JJ	et	al.		JASN.		2017	,12:	2263	-2274	
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1980s
French chemist isolates phlorizin from apple tree bark
Joseph von Mering demostrates that ingestion of
high doses of phlorizin causes glycosuria
First-in-human testing of phlorizin
Discovery of tissue distribution of SGLT1/2
Phlorizin inhibits SGLT1 and SGLT2
First SGLT2 inhibitor FDA approved
First dual SGLT1/2 inhibitor
pending approval
1886 19331835 1995 2014 2019
efferent
arteriole
normal PGC
afferent
arteriole
macula
densa
proximal
convoluted
tubule
distal
convoluted
tubule
collecting
duct
connecting
tubule
descending
limb of
Henle
ascending
limb of
Henle
Bowman’s
capsule
high PGC afferent
vasodilation
reduced
feedback from
macula
densa
increased NaCl and
glucose reabsorption
via SGLT-2
decreased
distal delivery
of NaCl
increased NaCl and
glucose filtration
~90% glucose
resorption via SGLT-2
~10% glucose
resorption via SGLT-1
Sodium-glucose co-transporter-2 (SGLT-2)
Sodium-glucose co-transporter-1 (SGLT-1)
Sodium (Na)
Chloride (Cl)
Glucose
PGC = pressure in glomerular capillary
A. Normal nephron B. Diabetic nephron
15	
Adapted	from	Alicic	et	al.,	Diabetes	2019;		68:	248-257.	
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Sodium	Glucose	Co-Transporters	1	and	2			
SGLT-1	and	SGLT-2	
• Under	normoglycemia	the	kidneys	reabsorb	all	of	
the	glucose	from	the	glomerular	filtrate		
• Energy	saving	measure	
• SLGT-	2	is	expressed	in	the	proximal,	SGLT-1	in	the	
distal	tubule		
	
~	90%	of	glucose	is	reabsorbed	via	SGLT-2	
~	10%	via	SGLT-1		
U.S.	Approved	and	Approval-Pending		SGLT2	
and	SGLT1	And	SGLT2	Inhibitors		
• canagliflozin	(Invokana)	–	March	2013		
• dapagliflozin	(Farxiga)	–	January	2014	
• empagliflozin	(Jardiance)	–	August	2014	
• ertugliflozin	(Steglatro)	–	2017	
• sotagliflozin	(Zynquista)	–	pending		
17	
Metabolic	Effects	of	SGLT-2	Inhibition	
• Glucose	loss	of	70-80	g/day	
• Weight	loss		
• Natriuresis	and	osmouresis		with	contraction	of	
plasma	volume	and	increase	in	hematocrit	and	
albumin	
• Reduction	in	BP		
• Reduction	in	uric	acid	level	
• Concerns	of	diabetic	ketoacidosis			
• Concerns	of	AKI		and		hyperkalemia		
Thomas	and	Cherney	(2018)	Diabetologia	DOI	10.1007/s00125-018-4669-0	
Mazidi	M	et	al.	J	Am	Heart	Assoc.	2017,	6:e004007	
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	CardioVascular	Outcomes	(CVO)	Trials			
• Since	December	2008,	the	U.S.	FDA	requires	that	the	
cardiovascular	(CV)	safety	of	all	new	drugs	for	diabetes	
be	demonstrated	to	exclude	an	unacceptable	increased	
relative	CV	risk		
• Non-inferiority	trials	to	extend	minimum	2	years	and	
enroll		a	more	vulnerable	population	with	DM2		
• 	Higher	CV	risk	are		“patients	with	relatively	advanced	
disease,	elderly	patients,	and	patients	with	some	degree	
of	renal	impairment”		
 
 
Hirshberg	B	et	al.,	Diabetes	Care	2011;	34:	101-106	
CV safety trials with drugs for type 2 
diabetes. 
 Mannucci	E	et	al.	Diabetes	Care	2016	
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Cardiovascular	
Outcome	Event	Trial	in	
Type	2	Diabetes	
Mellitus	Patients		
(EMPA-REG)			
• 7,020	DM2	participants		
• 10mg,	25	mg	of	
empagliflozin	or	placebo	
(	1:1:1	fashion)		
• Mean	age	63	yrs.	
• Follow	up	:	3	years	
• DM2	dx	>	10	years	
• H/O	MI	(	high	CV	risk)		
• eGFR	>	30	ml/min/1.73m²		
Canagliflozin	
Cardiovascular	
Assessment	Study	
(CANVAS)	Program		
• 10,142	DM2	participants	
• Canagliflozin	vs.	placebo		
• Mean	age	63	yrs.	
• Follow-up	:	2.4	years	
• DM	2	dx	>	10	yrs.	
• High	CV	risk		
• eGFR	>	30ml/min/1.73m²	
  Zinman	B	et	al.	N	Engl	J	Med	2015;373:2117	
Cardiovascular	Outcomes	and	Death	from	Any	Cause	
EMPA	-	REG		
	EMPA-REG	Sub-group	Analysis		
Kidney	Outcomes	in	Patients	with	DKD		
• 	2,000	participant	had	DKD:	26%	had	an	
eGFR	between	30-60	ml/min/1.73	m2,	and	
close	to	40%	of	participants	had	albuminuria	
(29%	with	microalbuminuria		and	11%	with	
macroalbuminuria)	
• Subgroup	analyses	of	participants	with	eGFR	
<60	mL/min/1.73	m2	or	macroalbuminuria	
	Zinman	B	et	al.	N	Engl	J	Med	2015;373:2117	
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			Wanner	C	et	al.	N	Engl	J	Med.	2016;375:323	
Key	Kidney	Outcomes	in	EMPA-REG	
Doubling	of	SCr		
44%	relative	risk	
reduction	(1.5%	vs.	
2.6%)		
Progression	to	
macroalbuminuria		
38%	relative	risk	
reduction		
Initiation	of	RRT	
55%	relative	risk	
reduction	
Slowing	GFR	decline		
0.19	±	0.11	vs.	
1.67±0.13	ml/min/1.73	
m2/per	year,	P	<	0.001)		
Neal	B	et	al.	N	Engl	J	Med,	2017;377:644-657.	
Cardiovascular	Outcomes	in	the	Integrated	CANVAS	
Program.	
Neal	B	et	al.	N	Engl	J	Med	2017;377:644-657.	
Effects of Canagliflozin on Cardiovascular, Kidney,  Hospitalization, 
and Death Events in the Integrated CANVAS Program. 
Hospitalization	for	
Heart	Failure		
33%	relative	risk	
reduction	
Progression	of	
albuminuria		
27%	relative	risk	
reduction		
Composite	kidney	
outcome	(40%	
reduction	in	eGFR,	
RRT,	Death	from	
Kidney	causes	
40	%	relative	risk	
reduction		
